Oxford BioDynamics Plc
LSE:OBD

Jigglypop Analysis For Oxford BioDynamics Plc 🤓

Oxford BioDynamics trades at 0.263p, hugging the 52-week floor (low 0.203p, high 0.85p) and sitting below its 200-day average (0.388p) but in line with the 50-day (0.262p). At a c.£11.3m market cap, this is firmly micro-cap territory. While annual results showed higher revenue, a narrower loss and rising monthly PSE orders, the October fundraise and ongoing need for working capital underline execution and dilution risk. In this context, proximity to the bottom of the range does not scream “value”; it flags a high-beta setup awaiting catalysts from licensing, distribution and broader test adoption. Sentiment: speculative, with upside torque if commercial traction accelerates, but technicals and recent capital raises argue for caution until the trend turns and cash runway clarifies further.

About Oxford BioDynamics Plc 👋

Oxford BioDynamics Plc and its subsidiaries operate as a biotechnology company focused on developing and commercializing precision medicine tests for serious diseases in the United States and the United Kingdom. The company offers EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test that predicts an individual patient’s likely response to checkpoint inhibitor immunotherapy. EpiSwitch is a proprietary technology platform that enables screening, assessment, validation, and monitoring of 3D genomic biomarkers. Its products include the EpiSwitch Prostate Screening Test (PSE) for prostate cancer; EpiSwitch CiRT for forecasting response to checkpoint inhibitor therapy; EpiSwitch Orion, a cloud platform built on Google Cloud; and the EpiSwitch Explorer Array Kit, which supports advanced analysis of 3D regulatory control points. The company was founded in 2007 and is headquartered in Oxford, United Kingdom.